Particle Health vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Particle Health provides a health data exchange API enabling healthcare apps to access longitudinal patient records from national networks with a single integration.
About
Particle Health is a health data exchange company founded in 2018 that provides developers and healthcare companies with a single API to access patient clinical records from national health information networks including CommonWell, Carequality, and others. The company abstracts the complexity of connecting to dozens of regional health information exchanges and national networks behind a simple developer-friendly API, enabling healthcare applications to retrieve longitudinal patient records including medical history, lab results, diagnoses, and medications from any participating provider. Particle raised $60M and serves digital health companies, telehealth platforms, health plans, and healthcare analytics firms that need access to real-world patient data to power clinical decision support, care management, and value-based care programs. The company provides HIPAA-compliant data access with identity verification and purpose-of-treatment validation to ensure appropriate use of patient records. Particle's API approach reduces the time and cost for healthcare companies to build clinical data infrastructure from months of complex integrations to days of API implementation.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.